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Abstract: Vascular remodeling is a characteristic feature of cardiovascular diseases. Altered cellular
processes of vascular smooth muscle cells (VSMCs) is a crucial component in vascular remodeling.
Histone deacetylase inhibitor (HDACI), butyrate, arrests VSMC proliferation and promotes cell
growth. The objective of the study is to determine the mechanism of butyrate-induced VSMC growth.
Using proliferating VSMCs exposed to 5 mM butyrate, immunoblotting studies are performed
to determine whether PI3K/Akt pathway that regulates different cellular effects is a target of
butyrate-induced VSMC growth. Butyrate inhibits phosphorylation-dependent activation of PI3K,
PDK1, and Akt, eliciting differential effects on downstream targets of Akt. Along with previously
reported Ser9 phosphorylation-mediated GSK3 inactivation leading to stability, increased expression
and accumulation of cyclin D1, and epigenetic histone modifications, inactivation of Akt by butyrate
results in: transcriptional activation of FOXO1 and FOXO3 promoting G1 arrest through p21Cip1/Waf1
and p15INK4B upregulation; inactivation of mTOR inhibiting activation of its targets p70S6K and
4E-BP1 impeding protein synthesis; inhibition of caspase 3 cleavage and downregulation of PARP
preventing apoptosis. Our findings imply butyrate abrogates Akt activation, causing differential
effects on Akt targets promoting convergence of cross-talk between their complimentary actions
leading to VSMC growth by arresting proliferation and inhibiting apoptosis through its effect on dual
targets, HDAC activity and PI3K/Akt pathway network.
Keywords: vascular smooth muscle cells; butyrate; histone deacetylase inhibitor; signaling; Akt

1. Introduction
Vascular remodeling is a characteristic pathological trait of many of the cardiovascular diseases
and disorders, including atherosclerosis and restenosis through the changes in cell proliferation,
cell growth, apoptosis, and differentiation of vascular cells in concert with vascular homeostasis.
Cardiovascular disease continues to be a major health concern in spite of great strides that
have been made in understanding the pathogenesis and management of the disease [1–3]. This
suggests that besides the known causes and associated risk factors, there may be other mechanisms
playing a role in cardiovascular events. Recent upsurge in epigenetic research discloses that
epigenetic processes are normal events that are vital to normal development and functioning of
organisms [2,4,5], and also instigated by many factors including environmental agents, lifestyle
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habits, dietary factors, aging and behavior [2,4–6]. Epigenetic processes mediated through histone
modifications, DNA methylation and microRNAs impose an added level of regulation by modulating
expression of critical genes that influence several cellular effects which are important to normal
physiology [2,4,5,7–11]. Dysregulation of epigenetic processes has been linked to several diseases
especially in cancer pathogenesis [4,12–16]. Cardiovascular epigenetics is a relatively unexplored
area of biomedical research. Epigenetic components in cardiovascular disease pathways, including
the pathways linked to atherosclerosis, are now being investigated to understand their role in
the pathogenesis [17–19]. Understanding the significance of dysregulated epigenetic changes in
the development of disease offers an effective therapeutic strategy for different diseases including
atherosclerosis- and restenosis-associated vessel remodeling.
Histones are targets of several different transient and reversible site-specific covalent
post-translational modifications (PTMs) such as acetylation, methylation, phosphorylation, sumoylation
and ADP-ribosylation. Reversible modifications of histones by acetylation alter chromatin structure,
dynamics, promoter accessibility and recruitment of histone modifiers to promote changes in gene
functions by affecting gene expressions [5,20–22]. Histone acetyltransferases (HATs) and histone
deacetylases (HDACs) are responsible for writing and erasing acetylation marks on lysine residues
of histone N-terminal tails, and more than 50 different non-histone proteins [21]. Counterbalancing
activities of these enzymes are crucial to the regulation of gene expressions by facilitating essential
processes, including transcription, replication and repair processes [5,20,21]. Importantly, inhibition
of HDACs activity has been exploited in reactivating transcriptionally silent tumor suppressor
genes such as p21Cip1/WAF1 to arrest cancer cell proliferation and growth by promoting histone
acetylation [22–25]. This paved the way to the development of HDAC inhibitors (HDACIs) as a
new class of anti-cancer drugs consisting of diverse sets of compounds, including both natural and
synthetically produced compounds varying in structure, specificity and biological activity [21,22].
Several of these inhibitors have been used in clinical trials of different diseases [2,4,16,21,26]. Moreover,
HDACIs cause an array of cell-type specific cellular effects in vitro and in vivo, including inhibition of
cell proliferation, stimulation of cell differentiation and/or apoptosis, and migration in non-cancer and
cancer cells [2,21–25,27–37].
Butyrate, a fermentation product of dietary fiber and a long known natural HDACI, also causes
a variety of cellular effects such as cell-cycle arrest in G1-phase, change in cellular morphology
and size, stimulate cell differentiation and/or induce apoptosis in different non-cancerous and
cancerous cells [21–25,27–37]. Our earlier studies [23,24,34,36] and studies from other investigators
have shown that butyrate arrests vascular smooth muscle cell (VSMC) proliferation and causes
antimigratory effects, the crucial factors in the pathogenesis of vascular proliferative diseases that
include atherosclerosis, arterial restenosis and hypertension [2,3,37–40]. In addition to antiproliferative
and antimigratory effects, butyrate also causes anti-oxidant and anti-inflammatory effects displaying
potential antiatherogenic chemopreventive and chemotherapeutic properties [41]. Furthermore,
our studies have shown that butyrate arrests proliferating VSMCs in G1-phase by downregulating
cyclin-dependent kinases 4 (cdk4), cdk6 and cdk2 and upregulating Cip/Kip and INK families of
cdk inhibitors. Consequently, this prevents entry into S-phase due to inhibition of phosphorylation
of retinoblastoma protein (Rb) [24]. Interestingly, butyrate treatment of proliferating VSMCs causes
upregulation of cyclin D1 and alters cellular morphology and size promoting VSMC growth [23,24,36],
unlike trichostatin A, another HDACI [36]. Our earlier study suggests that stabilization of cyclin D1
due to inhibition of cyclin D1 degradation by inactive glycogen synthase kinase 3(GSK3) combined
with increase in cyclin D1 synthesis contribute to increased cyclin D1 level in butyrate-treated VSMCs.
However, the underlying molecular mechanisms accountable for butyrate’s unusual effect on cyclin D1
level and altered cellular morphology of VSMCs was not clear. This is due to the realization that GSK3
may have a role in butyrate-induced VSMC effects [24,36] compounded with the knowledge that HATs
and HDACs can modulate several non-histone substrates, that include signal transduction proteins
and transcription factors by acetylation and deacetylation besides affecting gene expression [42,43].
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Figure 4. Inhibition of Akt activation by butyrate. VSMCs were treated with (BA) or without (Con)
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proliferation and cellular changes leading to cell growth, we examined the effect of butyrate
treatment on FOXO transcription factors, caspase 3, PARP and mTOR.
2.5.1. Impact of Butyrate-Inhibited Akt Activation on FOXO1 and FOXO3 Transcription Factors
supports survivalAkt
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apoptosis
through
inhibition Factors
of function
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of Butyrate-Inhibited
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Transcription
or expression of proapoptotic proteins and processes. FOXO proteins, a subgroup of Forkhead
Active Akt supports survival of cells by blocking apoptosis through inhibition of function or
transcription factors, are direct targets of Akt, which regulate transcription of distinctly different
expression of proapoptotic proteins and processes. FOXO proteins, a subgroup of Forkhead
groups of genes, depending on the cellular context to produce context-specific phenotypic effects.
transcription factors, are direct targets of Akt, which regulate transcription of distinctly different
Primarily, Akt-mediated phosphorylation of FOXO proteins suppresses activation of FOXO proteins
groups of genes, depending on the cellular context to produce context-specific phenotypic effects.
blocking transcription of genes linked to cell-cycle arrest or apoptosis [48–50]. Phosphorylation of
Primarily, Akt-mediated phosphorylation of FOXO proteins suppresses activation of FOXO proteins
FOXO proteins by Akt stimulates their association with 14-3-3 proteins, causing their translocation
blocking transcription of genes linked to cell-cycle arrest or apoptosis [48–50]. Phosphorylation of
from the nucleus to the cytoplasm, thus preventing their transcriptional activity due to cytoplasmic
FOXO proteins by Akt stimulates their association with 14-3-3 proteins, causing their translocation
sequestration. To examine the impact of butyrate-inhibited Akt activation on the transcriptional
from the nucleus to the cytoplasm, thus preventing their transcriptional activity due to cytoplasmic
activity of FOXO proteins, the phosphorylation state of FOXO1 (Figure 5) and FOXO3, which is also
sequestration. To examine the impact of butyrate-inhibited Akt activation on the transcriptional
referred to as FOXO3a (Figure 6) was analyzed by Western blot analysis. Butyrate treatment of VSMCs
activity of FOXO proteins, the phosphorylation state of FOXO1 (Figure 5) and FOXO3, which is also
significantly reduced phosphorylation of FOXO1 at Ser256 (Figure 5A) and at Ser329 (Figure 5B) after
referred to as FOXO3a (Figure 6) was analyzed by Western blot analysis. Butyrate treatment of
24 hours of treatment, compared to respective untreated VSMCs. Butyrate treatment also causes
VSMCs significantly reduced phosphorylation of FOXO1 at Ser256 (Figure 5A) and at Ser329 (Figure
inhibition of phosphorylation of FOXO3 at Ser253 (Figure 6B) and at Ser318/321 (Figure 6C) compared
5B) after 24 hours of treatment, compared to respective untreated VSMCs. Butyrate treatment also
to respective untreated controls. These results indicate that butyrate-induced inactivation of Akt
causes inhibition of phosphorylation of FOXO3 at Ser253 (Figure 6B) and at Ser318/321 (Figure 6C)
compared to respective untreated controls. These results indicate that butyrate-induced inactivation
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Figure 6. Assessment of butyrate effect on FOXO3. Cell lysates prepared from VSMCs treated with (BA)
Figure 6. Assessment of butyrate effect on FOXO3. Cell lysates prepared from VSMCs treated with
or without (Con) butyrate for indicated periods were subjected to Western blot analysis. (A) Analysis
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modulating intrinsic mitochondrial pathway of apoptosis through its direct targets FOXO proteins
and GSK3 [48–52]. Even though butyrate-induced changes in cellular morphology of VSMCs does
apoptosis
we still examined
the we
effect
butyrate on
state
of caspase
andstate
PARP
not
appear[23,24,36,53],
to indicate apoptosis
[23,24,36,53],
stillofexamined
the the
effect
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on3the
of
(Figure
7).
The
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Figure 7. Evaluation of butyrate effect on caspase 3 and PARP in VSMCs. Cell lysates prepared from
Figure 7. Evaluation of butyrate effect on caspase 3 and PARP in VSMCs. Cell lysates prepared from
VSMCs treated with (BA) or without (Con) butyrate were processed for Western blot analyses using
VSMCs treated with (BA) or without (Con) butyrate were processed for Western blot analyses using
antibodies specific to respective proteins. (A) Caspase 3 exhibits no activation both in control and
antibodies specific to respective proteins. (A) Caspase 3 exhibits no activation both in control and
butyrate-treated VSMCs except for trace level of cleaved caspase 3 in VSMCs treated with butyrate for
butyrate-treated VSMCs except for trace level of cleaved caspase 3 in VSMCs treated with butyrate
30 h (B) Full length PARP was determined by immunoblotting with antibody specific to full length
for 30 h @@
(B) Full length PARP was determined by immunoblotting with antibody specific to full length
PARP (
p < 0.001 vs 6 h control and ** p < 0.001 vs respective control). (C) Cleaved PARP was
PARP (@@ p < 0.001 vs 6 h control and ** p < 0.001 vs respective control).
(C) Cleaved PARP was assessed
assessed by probing with antibody specific to cleaved PARP (@@ p < 0.001 vs 6 h control but no cleaved
by probing with antibody specific to cleaved PARP (@@ p < 0.001 vs 6 h control but no cleaved PARP
PARP was detected in treated VSMCs (** p < 0.001 vs respective control).
was detected in treated VSMCs (** p < 0.001 vs respective control).
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assessed by Western blotting (Figure 8A). The results displayed in Figure 8A reveal butyrate
by downregulating mTOR phosphorylation. This observation agrees with butyrate-inhibited Akt
treatment inhibits activation of mTOR by downregulating mTOR phosphorylation. This observation
activation (Figure 4).
agrees with butyrate-inhibited Akt activation (Figure 4).
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Figure 8. Inhibition of activation of mTOR and its downstream targets by butyrate in VSMCs. Cell
Figure 8. Inhibition of activation of mTOR and its downstream targets by butyrate in VSMCs. Cell
lysates prepared from VSMCs treated with (BA) or without (Con) butyrate were analyzed by Western
lysates prepared from VSMCs treated with (BA) or without (Con) butyrate were analyzed by Western
blotting using antibodies specific to (A) phosphorylated mTOR, (B) Phosphorylated p70S6 kinase, (C)
blotting using antibodies specific to (A) phosphorylated mTOR, (B) Phosphorylated p70S6 kinase, (C)
phosphorylated S6 ribosomal protein and (D) phosphorylated 4E-BP1. Appropriate second antibodies
phosphorylated S6 ribosomal protein and (D) phosphorylated 4E-BP1. Appropriate second
labelled with IRDye 680LT or IRDye 800CW were used for detecting target proteins. LI-COR CLx
antibodies labelled with IRDye 680LT or IRDye 800CW were used for detecting target proteins. LIimaging system and Image Studio software were used for scanning and quantitating signal intensities.
COR CLx imaging system and Image Studio software were used for scanning and quantitating signal
(* p < 0.01 vs Control).
intensities. (* p < 0.01 vs Control).
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Upon phosphorylation-dependent activation, mTOR upregulates protein synthesis by exerting its
Upon phosphorylation-dependent activation, mTOR upregulates protein synthesis by exerting
kinase activity on its downstream target proteins p70S6 kinase and eukaryotic translation initiation
its kinase activity on its downstream target proteins p70S6 kinase and eukaryotic translation
factor-4E (eIF4E)-binding protein (4E-BP1), the key regulators of ribosome synthesis and mRNA
initiation factor-4E (eIF4E)-binding protein (4E-BP1), the key regulators of ribosome synthesis and
translation [48,54]. Activated mTOR phosphorylates p70S6kinase, which in turn phosphorylates
mRNA translation [48,54]. Activated mTOR phosphorylates p70S6kinase, which in turn
ribosomal S6 protein increasing general protein synthesis. Activated mTOR stimulates cap-dependent
phosphorylates ribosomal S6 protein increasing general protein synthesis. Activated mTOR
mRNA translation by phosphorylating 4E-BP1 and releasing it from inhibiting its binding partner,
stimulates cap-dependent mRNA translation by phosphorylating 4E-BP1 and releasing it from
eIF4E. To confirm inhibition of mTOR activation in butyrate-treated VSMCs, the phosphorylation
inhibiting its binding partner, eIF4E. To confirm inhibition of mTOR activation in butyrate-treated
state of downstream targets of mTOR, including p70S6 kinase (Figure 8B), ribosomal S6 protein
VSMCs, the phosphorylation state of downstream targets of mTOR, including p70S6 kinase (Figure
(Figure 8C) and 4E-BP1 (Figure 8D) were determined by Western blotting. The results displayed
8B), ribosomal S6 protein (Figure 8C) and 4E-BP1 (Figure 8D) were determined by Western blotting.
in Figure 8B–D corroborate with the attenuation of mTOR activation in butyrate-treated VSMCs.
The results displayed in Figure 8B, 8C and 8D corroborate with the attenuation of mTOR activation
Furthermore, attenuation of mTOR and its downstream targets appears to indicate butyrate-induced
in butyrate-treated VSMCs. Furthermore, attenuation of mTOR and its downstream targets appears
cell growth is not mediated through mTOR.
to indicate butyrate-induced cell growth is not mediated through mTOR.
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3. Discussion
VSMCs play critical roles in atherosclerosis and restenosis-associated vascular remodeling leading
to neointimal hyperplasia [2,3,37–39,57–59]. Their vulnerability to proliferate and migrate to the
site of injury, to deposit extracellular matrix and secrete chemokines, cytokines and reactive oxygen
species in response to injury leads to neointimal hyperplasia resulting in severe vascular events like
heart attack, stroke and peripheral artery disease. Apoptosis of VSMCs is also a critical factor in
atherosclerotic plaque-dependent cardiovascular events such as stroke, myocardial infarction and
sudden death [2,49,60]. Loss of VSMCs via apoptosis provokes loss of structural integrity of the
atherosclerotic fibrous cap that is susceptible to rupturing. Since cardiovascular disease continues to
be a major health concern globally, any new interventional therapeutic development that reverses or
prevents progression of atherosclerosis- and restenosis-associated remodeling in the vascular structural
blueprint has significance in reducing the cardiovascular health menace. In this scenario, HDACIs
appear to have potential use because of their effects on cell proliferation, survival and apoptosis.
HDACIs have been highly implicated in the treatment of different cancers and other diseases [12–16]
and recently in vascular diseases [2,4,22,37–39].
Butyrate is a natural HDACI and a fermentation product of dietary fiber that potentially mediates
the beneficial effects of dietary fiber. The physiological concentration of butyrate is about 10 to
20 mM based on the type of dietary fiber consumed. For most cell culture and animal studies,
mM concentrations of butyrate are used ranging from 0.5 mM to 10 mM. In many studies 5 mM
concentration appears to be effective concentration [29,33,37], including in our study [23]. Our earlier
study used 0.5 mM to 8 mM butyrate to determine concentration-dependent effect of butyrate on VSMCs
proliferation [23]. At 5 mM and higher than 5 mM up to 8 mM concentration, butyrate completely
inhibits VSMC proliferation, but stimulates VSMC growth by increasing cellular size and mass, not by
cell number. Furthermore, butyrate has been shown to elicit a multitude of cellular responses that
support antiatherogenic effects from our previous studies [23,24,34,36,41] and studies from other
investigators [37–40]. Our earlier studies also reveal that, in addition to inhibiting proliferation,
butyrate also alters cellular size and morphology of VSMCs stimulating VSMC growth [23,24,36,53],
and its effects are reversible upon its removal [34,53]. VSMCs react to butyrate treatment by gradually
increasing their size and changing shape. Moreover, the scope of increase in size relies on the initial
densities of the cultures [34]. Although the exact underlying mechanisms mediating these different
cellular effects of butyrate are not clear, outcomes of the present study suggest butyrate effects on
VSMCs are mediated through disparate effects on dual targets, HDAC activity and PI3K/Akt signaling
network (Figure 9). HDAC activity that regulates gene expression by histone epigenetic modifications,
causing chromatin remodeling [24,36], and PI3K/Akt signaling network that promotes activation or
inactivation of certain effectors of PI3K/Akt pathway, are central to cell growth, proliferation, survival
and apoptosis, respectively.
PI3Ks are a family of dual protein and lipid kinases, which upon activation phosphorylate the
hydroxyl group at position 3 of the inositol ring of inositol phospholipids present in the plasma
membrane. Class I PI3Ks are heterodimers of 85kDa regulatory subunit p85 and 110 kDa catalytic
subunit p110, which are linked to an array of different functions. These functions include cell
growth, proliferation, differentiation, survival and migration [44–47]. The PI3K/Akt signaling pathway,
the pathway of Akt named after the upstream activator protein PI3K, plays a central role in several
different cellular functions. These include cell proliferation, growth, survival, apoptosis, migration,
differentiation, metabolism, and angiogenesis, which are important in cardiovascular function and
structural integrity [44–48]. Assessment of this pathway in butyrate-induced cellular effects on VSMCs
(Figure 1) discloses reduction in expression and inactivation of p85 regulatory subunit of PI3K, which
is used as a measure of PI3K activity (Figure 2). Activity of PI3K is routinely assayed by determining
the level of phosphorylated p85Tyr458 by Western blotting [61,62]. Furthermore, butyrate treatment
also inhibits activity of PDK1, the upstream activator of Akt (Figure 3). Butyrate treatment of VSMCs
inhibits phosphorylation of Ser241 of PDK1, which is required for its kinase activity. Therefore, it is
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depletion or inactivation of butyrate in the culture medium may be linked to the state of Akt
phosphorylation in 30 h butyrate-treated VSMCs. Despite these differences, butyrate treatment does
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Butyrate-inhibited Akt activation arrests VSMC proliferation promoting VSMC growth via
Figure 9. Butyrate-inhibited
its downstream targets. Increased expression of cyclin D1, and its stability due to inhibition of GSK3
activity along with increased expression of p21Cip1/Waf1 and p15INK4B through the activation of
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VSMCs
in G1-phase
(red arrows).
Additionally,
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of caspase
FOXO proteins
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butyrate
arrests
VSMCs
in G1-phase
(red arrows).
Additionally,
inhibition
of
3 activity and downregulation of PARP by butyrate inhibits apoptosis. Inhibition of mTOR-mediated
protein synthesis appears to have no effect on VSMC growth.

Our present study reveals increased phosphorylation of Thr308 and Ser473 residues of Akt in
6 h and 24 h untreated VSMCs, compared to corresponding butyrate-treated VSMCs. However,
compared to 6 h untreated VSMCs, 24 h and 30 h untreated VSMCs exhibited significant reduction in
phosphorylation of both residues of Akt. This inhibition of Akt activation in 24 h and 30 h untreated
VSMCs is not unusual. Studies have shown that stimulation of cells with serum or growth factors,
induces Akt activation [29,37,63–65]. This Akt activation, from very low to a period of increase in
activation by phosphorylation, varies from minutes to hours to days, followed by reduction in Akt
phosphorylation, depending on the cell type and cellular context [29,37,63–65]. Regarding appearance
of slight reversal of butyrate inhibition of Thr308 and Ser473 phosphorylation in 30 h butyrate-treated
VSMCs, it is possible that it may be linked to continuous incubation in the same culture medium for 30 h,
without replenishing with fresh culture medium containing butyrate. Considering that butyrate effects
are reversible upon removal of butyrate (34,53), it is possible that depletion or inactivation of butyrate
in the culture medium may be linked to the state of Akt phosphorylation in 30 h butyrate-treated
VSMCs. Despite these differences, butyrate treatment does inhibit Akt activation in VSMCs. Akt is
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the critical node of the PI3K/Akt pathway that is responsible for the regulation of different cellular
processes of PI3K/Akt pathway through the mediation of serine and/or threonine phosphorylation of
its downstream targets. Some of the important Akt targets that are essential to cardiovascular functions
and structural integrity include FOXO transcription factors, mTOR and GSK3. Inactivation of Akt by
butyrate differently affects FOXO transcription factors (Figures 5 and 6), caspase 3 and PARP (Figure 7),
mTOR (Figure 8), and GSK3 [36], ultimately promoting proliferation arrest and altered cellular size
and morphology. This causes VSMC growth, possibly through appropriate collaborative cross-talk
between the signal effectors of PI3K/Akt pathway (Figure 9).
Inhibition of cell proliferation by butyrate promotes different cellular effects including cell
survival, cell growth, cell differentiation or cell death depending on the cell type and cellular
context [24,28–33,36,37,40,41]. In serum-starved pulmonary arterial VSMCs (PAVSMCs), butyrate
treatment inhibits platelet-derived growth factor (PDGF)-induced proliferation and migration [37].
In bovine kidney epithelial cells butyrate induces apoptosis and cell-cycle arrest [28]. Butyrate
also inhibits growth of different tumor cells by inhibiting cell proliferation [30], promoting cell
differentiation [33], inducing apoptosis [29] and preventing cell migration [31]. Unlike in these cells,
our studies have shown that butyrate causes proliferation arrest and alters cellular morphology of
VSMCs by a cytostatic effect, promoting cell growth [23,24,36,53]. Akt plays a crucial role in different
cellular effects. Activation of Akt by phosphorylation of Ser473 and Thr308 residues is critical for
promoting proliferation, growth and survival in a signal-context manner to extracellular signals or
agents. Several studies reveal suppression of Akt activity is associated with the antiproliferative effect
of butyrate resulting in inhibition of cell migration [31,37] and apoptosis [29]. The present study reveals
suppression of Akt activation is associated with butyrate-induced VSMC growth by arresting VSMC
proliferation (Figure 4). While these different butyrate-induced cellular effects are associated with Akt
inactivation, it is the cellular environment and the ability of the cells to respond to their milieu that
appears to be the determinant of their cellular fate through appropriate regulation of downstream
targets of Akt [44–48].
Activated Akt elicits many cellular effects including cell survival, growth, proliferation, migration,
metabolism and apoptosis that are important for cardiovascular functions and structural integrity
through the mediation of serine and/or threonine phosphorylation of an assortment of downstream
targets. Phosphorylation by Akt can be inhibitory or stimulatory, thus, negatively or positively
suppressing or enhancing the activity of target proteins. Moreover, some crucial Akt targets including
FOXO transcription factors, mTOR and GSK3, control more than one cellular function and their
role may vary in a cell and signal-context dependent manner. As such, FOXO transcription factors,
mTOR and GSK3 control several cellular processes that include cell survival, growth, proliferation,
metabolism, and apoptosis. The role of these Akt targets in butyrate-induced cellular effects are not well
understood, particularly in butyrate-inhibited VSMC proliferation and altered cellular morphology.
Our present study reveals abrogation of Akt activation by butyrate differentially affects FOXO1 and
FOXO3 transcription factors, mTOR, caspase 3 and PARP, and GSK3 [36]. Convergence of cross-talk
between their actions apparently leads to proliferation arrest and altered morphology of VSMCs
leading to cell growth.
FOXO1 and FOXO3 proteins, members of a subgroup of Forkhead transcription factors, play
pivotal roles both in cell-cycle arrest, and/or apoptosis signaling by coordinating a cast of gene
expression that regulate cell survival and cell death [48–50]. Activated Akt directly phosphorylates
FOXO proteins impairing their DNA-binding activity but boosting their affinity for 14-3-3 chaperone
proteins, thus, facilitating export of FOXO-14-3-3 complex out of the nucleus to the cytoplasm.
Cytoplasmic sequestration of FOXO proteins blocks FOXO-dependent transcriptional activation.
Conversely, inactivation of Akt triggers transcriptional activation of FOXO proteins by promoting their
residence in the nucleus, eliciting expression of multiple target genes specific to cell-cycle arrest or
apoptosis depending on the cell type and cellular context [49,50,66]. Moreover, studies have shown
that FOXO proteins enhance cell-cycle arrest by upregulating the levels of different cyclin-dependent
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kinase (cdk) inhibitors that belong to the INK and Cip/Kip family as an essential part of the cytostatic
response by stimulating G1 arrest resulting in quiescence [24,67]. In the present study, inhibition of
FOXO1 (Figure 5) and FOXO3 (Figure 6) phosphorylation in butyrate-arrested VSMC proliferation
indicates transcriptional activation of FOXO proteins, especially those genes that promote cell-cycle
arrest. In concurrence with this possibility, our earlier studies have shown butyrate treatment of
VSMCs induces cell-cycle arrest and promotes entry to quiescence with no obvious signs of cell
death, along with upregulation of p21Cip1/Waf1 and p15INK4B [24,36]. Correspondingly, several
other studies also demonstrate FOXO proteins play a major role in cell-cycle arrest by enhancing
cdk inhibitors, p21Cip1/ Waf1 and p15INK4 levels [67]. Recent studies indicate that FOXO activity is
controlled by an intricate combination of post-translational modifications (PMTs) including acetylation,
methylation and ubiquitination, in addition to phosphorylation [68]. These modifications in turn
regulate their subcellular localization, expression level and DNA-binding activity. Considering that
butyrate is an inhibitor of Class I and Class II HDACs, it will be interesting to explore butyrate’s
influence on acetylation of FOXO proteins enhancing their transcriptional activation. Additional
studies are required to explore the impact of butyrate on transcriptional activation of FOXO proteins
that contributes to the cytostatic response [24,36].
A range of unrelated factors and conditions, including chemotherapeutic agents, loss of contact
with the extracellular matrix, DNA damage, and growth factor withdrawal can initiate the intrinsic
mitochondrial pathway of apoptosis, resulting in the activation of caspase cascade. Although several
studies reveal that butyrate arrests cell proliferation by inducing apoptosis [22,28,29], our studies
reveal that butyrate exerts a cytostatic response in VSMCs with no obvious signs of apoptosis [24,36,53].
To substantiate this observation, we examined butyrate’s effect on the activity state of caspase 3 and
PARP, representing caspase-dependent and caspase-independent mechanisms of apoptosis, respectively
(Figure 7). As expected, there was no overall change in the levels of intact caspase 3 in both untreated
and butyrate-treated cells, with the exception that sometimes a minimal cleavage of caspase 3 in
VSMCs treated for 30 h with butyrate was noticed (Figure 7A).
Interestingly, in butyrate-treated VSMCs, intact uncleaved PARP level was not only significantly
downregulated, but there was also no cleavage of PARP, compared to untreated VSMCs (Figure 7B,C).
Furthermore, significant increase in the levels of cleaved PARP fragment in both 24 h and 30 h
untreated VSMC cultures is surprising. It is possible that the presence of cleaved PARP in untreated
VSMCs may be linked to disintegration of cells that may have lost contact inhibition once the culture
becomes confluent. Although butyrate effects on caspase 3 and PARP further support that apoptosis is
not involved in butyrate-inhibited VSMC proliferation, the effects of butyrate on PARP is puzzling,
and at the same time exciting, because it may have therapeutic implications. PARP was initially
identified as the enzyme that detects and initiates repair of single-, double-stranded DNA breaks.
Recent studies recognize that it is a multifunctional enzyme, and its functions depend on its extent of
activation [69,70]. Besides its role in DNA-damage repair, it is a well-known apoptotic marker, and its
hyperactivation leads to accumulation of poly-ADP-ribose (PAR) and depletion of NAD+ and ATP,
causing caspase-independent apoptosis or necrotic cell death. Unwarranted hyperactivity of PARP
has been alluded to the pathogenesis of several diseases and disorders, including stroke, myocardial
infarction, inflammation, diabetes, cancer and neurodegenerative disorders [69,70]. In this scenario,
butyrate-induced downregulation of PARP appears to strengthen butyrate’s therapeutic potential in
other diseases besides its use as an anti-cancer agent. However, further clarification is required to
understand how butyrate regulates PARP.
Besides arresting proliferation and causing no cell death, butyrate alters cellular morphology of
VSMCs from their elongated bipolar morphology to a round and spread-out phenotype with increase
in sizes, implicating inhibition of cell proliferation by butyrate promotes cell growth [23,24,36,53]. Our
studies also observed the extent of size increase is dependent on the initial densities of the cultures,
and it is due to increase in mass, not due to increase in cell number. Recent studies indicate, increase in
cell size due to increase in growth is possible through two mechanisms: a cell-cycle-related mechanism
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through an increase in cyclin D1 level that prolongs the stay of the cells in G1-phase of the cell
cycle, and the mTORC1 signal pathway-mediated mechanism that boosts protein synthesis [71–74].
According to our previous studies, a cell-cycle related mechanism is linked to butyrate-induced cellular
growth [24,36]. In response to mitogenic signals, quiescent cells enter into G1-phase of the cell cycle,
increase cyclin D1 level, activate cyclin D1/cdk4 activity and stimulate protein synthesis prior to
transition to S-phase. However, in the presence of antiproliferative agents, cell-cycle progression is
arrested before the restriction point. This leads to inhibition of cyclin E/cdk2 activation and attenuation
of the movement of cells into S-phase. Consequently, it promotes increase in physical growth in
early G1-phase without progressing entry into S-phase [75,76]. Moreover, increased expression of the
INK and Cip/Kip families of cdk inhibitor complexes also contributes to cell-cycle arrest triggering
cell growth [24,36,77,78]. Correspondingly, our earlier studies demonstrate butyrate-induced cellular
changes of VSMCs were linked to butyrate effects on cell-cycle regulatory proteins. Butyrate not only
increases cyclin D1 level that is localized to nuclear regions, it also induces expression of cyclin D
type-specific cdk4/cdk6 inhibitor p15INK4B and universal cdk inhibitor p21Cip1/Waf1 that inhibit
G1/S-phase cdk complexes [24,36]. In general, most HDACIs arrest cell proliferation in G1-phase with
universal increased expression of p21Cip1/Waf1. Taken together, butyrate-induced enhanced levels of
both cyclin D1-specific cdk inhibitor p15INK4B and universal cdk inhibitor p21Cip1, and augmented
levels of cyclin D1 itself, force VSMCs to stay in G1-phase and grow in size, preventing proliferation by
restraining them from progressing into S-phase.
Our previous studies also reveal that increase in cyclin D1 levels is linked to increased synthesis and
increased stability, based on cyclin D1 transcription and phosphorylation state of GSK3, respectively [36].
GSK3 is an important downstream target of Akt that exists in two isoforms α and β, regulating
several cellular functions, including cell growth, survival, death, proliferation, and metabolism,
by its role in various signaling pathways that control the fate of the cell [49]. Activation of Akt
triggers inhibitory phosphorylation of GSK3, causing its inactivation via phosphorylating Ser9 on
GSK3α and Ser21on GSK3β, which permits cell proliferation [49,51,52]. Conversely, inhibition of Akt
activation in response to certain stimuli can cause cell-cycle arrest by activating GSK3 kinase activity
through dephosphorylation of GSK3 [36,52]. Activated GSK3 functions in cell-cycle regulation by
phosphorylating Thr286 on cyclin D1 that plays a crucial role in G1 to S-phase cell-cycle transition.
Although our earlier studies indicate GSK3 is phosphorylated and inactive in response to butyrate
treatment, the upstream signaling pathway linked to GSK3 inhibition in butyrate-arrested VSMC
proliferation was not investigated [36]. Interestingly, the present study reveals that inactivation of Akt,
the usual regulator of GSK3, by butyrate (Figure 4) was not linked to inactivation of GSK3 [36]. It is
possible protein kinases of other signaling pathways may be involved in the inhibitory phosphorylation
of GSK3 that stabilizes cyclin D1, by significantly inhibiting Thr286 phosphorylation-dependent
degradation of cyclin D1, thereby resulting in nuclear accumulation of cyclin D1 in G1-phase appears
to be responsible for cellular changes, and arrest of VSMCs in G1-phase.
Induction of protein synthesis in G1-phase is required for cell growth, and it is acknowledged that
mTOR signaling pathway and its downstream targets, p70 ribosomal S6 kinase (p70S6K) and eukaryotic
translation initiation factor 4E binding protein (4EBP1) dependent signals are key to regulating growth
by increasing protein synthesis [47,54,71–74]. Our present study reveals, mTOR is not required for
the butyrate-induced increase in size/growth of VSMCs. Treatment of VSMCs with butyrate inhibits
phosphorylation of mTOR, which inevitably leads to inhibition of phosphorylation of downstream
effectors of mTOR, p70S6 kinase and 4EBP1 (Figure 8). Considering the inactivation of Akt, the upstream
activator of mTOR pathway by butyrate, it is not surprising that mTOR pathway is inactivated. These
observations indicate, butyrate-induced increase in VSMC growth may involve mTOR-independent
pathways that control protein synthesis in VSMC growth. Similar mTOR- independent regulation of
protein synthesis, and cell growth have been reported in some cases [72,74]. The reasons for disparity
are not clear, but perhaps, different cell types have different degrees of necessity for mTOR in control of
their growth or probably alternate compensatory pathways are upregulated. In this regard, cyclin D1
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itself exhibits several cdk-independent functions, causing distinct cellular effects through its interaction
with more than 30 different transcription factors and transcription regulators, including HDACs and
HATs, which may contribute to VSMC growth [79].
4. Materials and Methods
4.1. Cell Culture and Treatment of VSMCs
Rat aortic VSMCs obtained from commercial source (Cell Applications Inc., San Diego, CA, USA)
were used for studies. They were cultured and maintained in Dulbecco’s modified Eagle’s medium
(DMEM) augmented with 10% fetal bovine serum, 100 Units of penicillin and 100 µg/ml streptomycin
(Atlanta Biologicals, Lawrenceville, GA), used as complete medium, in a humidified atmosphere of
5% CO2 at 37 ◦ C. Confluent cultures were subcultured by seeding the cells at a ratio of 1:4. One
day after seeding, proliferating cells were untreated or treated with 5 mM butyrate (Sigma-Aldrich
Chemical St. Louis, MO, USA) for indicated periods of time as described previously [24,36]. For all
studies, 5 mM butyrate concentration was used based on our previous concentration-dependent
studies [23,75]. Butyrate concentrations ranging from 0.5 mM to 8 mM revealed, 5 mM and higher than
5 mM up to 8 mM concentrations, completely inhibited VSMC proliferation causing no cytotoxicity or
apoptosis [23,75]. Cultures were fed with fresh complete medium containing butyrate or no butyrate
every other day unless otherwise mentioned. At the end of incubation period, VSMCs were collected
for analysis after washing with phosphate-buffered saline (PBS). Unless mentioned, results presented
are derived from two to three independent experiments. For all studies, third to tenth passage of
VSMCs was used.
4.2. Butyrate-Induced Cellular Effects on VSMCs
To determine the effect of butyrate on VSMC growth, one day after seeding, proliferating VSMCs
were treated with complete medium containing butyrate (BA) or no butyrate (Con) for 72 h. After 72 h
of treatment, cultures were washed with PBS and fixed in cold methanol for 5 minutes as described
previously, to assess butyrate-induced altered cellular morphology and increase in size that promotes
VSMC growth [24,36,41]. After fixing, washed with PBS three times, then blocked with 10% heat
inactivated horse serum (HS) in PBS for one hour at room temperature. After washing with PBS,
cultures were incubated with 1µg/ml Hoechst in 1.5% HS for 30 min. After incubation, cultures were
washed with PBS and used for fluorescence microscopy using a Nikon fluorescence microscope.
To demonstrate butyrate-induced VSMC growth is linked to proliferation arrest, VSMC cultures
exposed to butyrate for 72 h, as described above. After 72 h of treatment, cultures were washed
three times with sterile PBS and trypsinized with trypsin-EDTA. Cells were collected in DMEM and
centrifuged briefly at 3000 rpm at room temperature. The cell pellets were suspended in PBS and cell
numbers were counted by trypan blue exclusion method, using TC20 Automated cell counter from
Bio-Rad, as described by the manufacturer (Bio-Rad, Hercules, CA, USA).
4.3. Western Blot Analysis
For Western blot analysis, one day after seeding the cells, cultures were treated with complete
medium containing (BA) or no butyrate (Con) for indicated periods without replacing with fresh
culture medium. At the end of treatment period, cultures were washed with ice cold PBS. Total
cell lysates from experimental cultures were prepared and quantitated for protein concentration as
described previously [41]. Briefly, total cell lysates from experimental cultures were prepared by lysing
the cells in sodium dodecyl sulfate (SDS) sample buffer containing protease and phosphatase inhibitors
(5872, Cell Signaling Technology, Danvers, MA, USA) by gentle rocking for 10 min at 4 ◦ C. The lysates
were collected, and homogenized by passing through syringe and 21 gauge needle 15 times [41]. The
homogenates were centrifuged at 15,000 rpm for 15 min at 4 ◦ C. The supernatants were collected and
protein concentrations were determined with the BCA protein assay kit from Pierce Biotechnology
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(Rockford IL, USA). Required amounts of samples were denatured by heating at 90 ◦ C for 5 min, after
adding β-mercaptoethanol and SDS to a final concentration of 1% and 0.05%, respectively. Equal
amounts of protein from each sample were subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and separated proteins were electro-blotted onto PVDF membrane and
used for Western blotting.
Western blotting was performed first blocking the blots with Tris-buffered saline (TBS) containing
0.1% Tween 20 and 5% non-fat milk powder (Blotto sc-2324, Santa Cruz Biotechnology, Dallas TX, USA)
for 1 h at room temperature. Then the blots were incubated overnight at 4 ◦ C with appropriate primary
antibodies to detect activation and/or levels of target proteins with gentle agitation [24,36,41]. The
primary antibodies that were used include p85PI3Kinase (4257, 1:1000 dilution), phospho-p85PI3Kinase
(4228, 1:1000 dilution), phospho-Ser241PDK1 (3438, 1:1000 dilution), PDK1 (3062, 1:000 dilution) Akt1
(4691, 1:1000 dilution), phospho-Ser473Akt (4060, 1:1000 dilution), phospho-Thr308Akt (2965, 1:1000
dilution), phospho-Ser2448mTOR (5536, 1:1000 dilution), phospho-Thr389p70S6Kinase, (9234, 1:1000
dilution), phospho-Ser235/236-S6 ribosomal protein (4858, 1:1000 dilution), phospho-Thr37/46–4E-BP1
(2855, 1:1000 dilution), phospho-Ser318/321FOXO3a, (9465, 1:1000 dilution), phospho-Ser256FOXO1,
(9461, 1:1000 dilution), cleaved caspase 3 (9661, 1:1000 dilution), full length PARP (9532, 1:1000 dilution),
cleaved PARP (9545, 1:1000 dilution), ERK1/ERK2 (9102, anti-rabbit, 1:1000 dilution) and ERK1/ERK2
(9107, mouse monoclonal, 1:2000 dilution) from Cell Signaling Technology (Danvers, MA, USA).
FOXO3a (GTX62705, 1:2000 dilution) was from GeneTex (Irvin, CA, USA), Phospho-Ser329FOXO1
(ab52857, 1:2000 dilution) and phospho-Ser253FOXO3a (ab154786, 1:2000 dilution) from abcam
(Cambridge, MA, USA).
Following primary antibody incubation, the blots were incubated with species appropriate horse
radish peroxidase (HRP) conjugated anti-rabbit-HRP-linked secondary antibody (7074, 1:2000 dilution)
from Cell Signaling Technology (Danvers, MA, USA) or IRDye-conjugated goat anti-mouse IRDye
680LT (925-68020, 1:20,000 dilution) and goat anti-rabbit IRDye 800CW (925-32211, 1:15,000 dilution)
secondary antibodies from LI-COR, Inc. (Lincoln, NE, USA). Blots probed with HRP-conjugated
secondary antibodies were processed for chemiluminescence immunodetection using luminol reagent
from Santa Cruz Biotechnology (Dallas, TX, USA). Band intensities were measured and analyzed
by using Molecular Imager Pro Plus MultiImager system and Quantity One software from Bio-Rad
(Hercules, CA, USA). Blots that were probed with IRDye-conjugated secondary antibodies were
imaged on Odyssey CLx imager and band intensities were measured and quantitative analysis was
performed using Image Studio software from LI-COR, Inc. (Lincoln, NE, USA). For normalizing
protein loading, blots were probed with anti-ERK1/ERK2 antibodies, which is unaffected in response to
butyrate treatment [24,36,41] unlike routinely used normalizing controls such as GAPDH and β-actin.
For some phosphorylated signal transduction pathway proteins, the membranes were probed with
antibodies specific to their respective total protein to normalize the protein loading.
4.4. Data Analysis
Statistical analysis was performed using GraphPad Prism version 5 software from GraphPad
Software Inc (La Jolla, CA, USA). Statistical differences between controls and treatment groups
were analyzed by one-way analysis of variance (ANOVA) with Bonferroni multiple comparison test.
Statistically significant differences between data sets were calculated at p < 0.01 and p < 0.001.
5. Conclusions
In conclusion, butyrate’s cellular effects on VSMCs are mediated through disparate effects on
dual targets, HDAC activity and PI3k/Akt signaling network. Butyrate arrests VSMC proliferation
and inhibits cell death, promoting cell growth by increasing cellular size. Through its HDAC
inhibitory functionality, butyrate not only alters expression of epigenetically regulated genes associated
with cell-cycle regulation and PI3K/Akt signaling network, but also interferes with PI3K/Akt signal
transduction pathway through PTMs of Akt and Akt targets. Increased expression of cyclin DI and D3,
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p15INK4, p21Cip1/Waf1 [24,36] and clusterin (our unpublished data) in butyrate-treated VSMCs indicate
multiple proteins are associated with change in VSMC phenotype. Considering cardiovascular disease
continues to be a major health concern globally, any new interventional therapeutic development that
reverses or prevents progression of atherosclerosis- and restenosis-associated remodeling of vascular
structural blueprint has significance in reducing cardiovascular health menace. In this scenario,
HDACIs, particularly the dietary HDACI butyrate, exhibits chemopreventive and chemotherapeutic
potential, which have been already dominated in the treatment of different cancers and other
diseases. Besides, butyrate-induced downregulation of PARP appears to strengthen butyrate’s
therapeutic potential. Unwarranted hyperactivity of PARP has been linked to pathogenesis of several
diseases and disorders including stroke, myocardial infarction, inflammation, diabetes, cancer and
neurodegenerative disorders [64,65]. However, further clarification is required to understand how
butyrate regulates PARP and its significance in vascular remodeling.
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